These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 21192233)

  • 1. Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings.
    Phillips AN; Pillay D; Garnett G; Bennett D; Vitoria M; Cambiano V; Lundgren J
    AIDS; 2011 Mar; 25(6):843-50. PubMed ID: 21192233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited.
    Orrell C; Harling G; Lawn SD; Kaplan R; McNally M; Bekker LG; Wood R
    Antivir Ther; 2007; 12(1):83-8. PubMed ID: 17503751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost effectiveness of antiretroviral treatment strategies in resource-limited settings.
    Bishai D; Colchero A; Durack DT
    AIDS; 2007 Jun; 21(10):1333-40. PubMed ID: 17545710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of monitoring virologic responses to antiretroviral therapy in HIV-infected children in resource-limited settings.
    Schneider K; Puthanakit T; Kerr S; Law MG; Cooper DA; Donovan B; Phanuphak N; Sirisanthana V; Ananworanich J; Ohata J; Wilson DP
    AIDS; 2011 Jun; 25(9):1143-51. PubMed ID: 21505319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initiation of antiretroviral therapy among pregnant women in resource-limited countries: CD4+ cell count response and program retention.
    Toro PL; Katyal M; Carter RJ; Myer L; El-Sadr WM; Nash D; Abrams EJ;
    AIDS; 2010 Feb; 24(4):515-24. PubMed ID: 19996939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond first-line HIV treatment regimens: the current state of antiretroviral regimens, viral load monitoring, and resistance testing in resource-limited settings.
    Kumarasamy N; Krishnan S
    Curr Opin HIV AIDS; 2013 Nov; 8(6):586-90. PubMed ID: 24100872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria.
    van Oosterhout JJ; Brown L; Weigel R; Kumwenda JJ; Mzinganjira D; Saukila N; Mhango B; Hartung T; Phiri S; Hosseinipour MC
    Trop Med Int Health; 2009 Aug; 14(8):856-61. PubMed ID: 19552661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secure antiretroviral therapy delivery in a resource-limited setting: streamlined to minimize drug resistance and expense.
    Kitkungvan D; Apisarnthanarak A; Laowansiri P; Mundy LM
    HIV Med; 2008 Oct; 9(8):636-41. PubMed ID: 18643857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda.
    Mills EJ; Bakanda C; Birungi J; Mwesigwa R; Chan K; Ford N; Hogg RS; Cooper C
    AIDS; 2011 Mar; 25(6):851-5. PubMed ID: 21330903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
    Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model.
    Phillips AN; Pillay D; Miners AH; Bennett DE; Gilks CF; Lundgren JD
    Lancet; 2008 Apr; 371(9622):1443-51. PubMed ID: 18440426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges in implementing HIV laboratory monitoring in resource-constrained settings: how to do more with less.
    Bélec L; Bonn JP
    Future Microbiol; 2011 Nov; 6(11):1251-60. PubMed ID: 22082287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
    Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D
    Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term antiretroviral therapy to prevent mother-to-child transmission is safe and results in a sustained increase in CD4 T-cell counts in HIV-1-infected mothers.
    Palacios R; Senise J; Vaz M; Diaz R; Castelo A
    HIV Med; 2009 Mar; 10(3):157-62. PubMed ID: 19245537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of drug resistance and importance of viral load measurements in Honduran HIV-infected patients failing antiretroviral treatment.
    Murillo W; de Rivera IL; Parham L; Jovel E; Palou E; Karlsson AC; Albert J
    HIV Med; 2010 Feb; 11(2):95-103. PubMed ID: 19686436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virological characterization of an infection with a dual-tropic, multidrug-resistant HIV-1 and further evolution on antiretroviral therapy.
    Masquelier B; Capdepont S; Neau D; Peuchant O; Taupin JL; Coakley E; Lie Y; Carpentier W; Dabis F; Fleury HJ;
    AIDS; 2007 Jan; 21(1):103-6. PubMed ID: 17148975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of time to undetectable HIV viral load in the first 16 weeks after the start of three and four antiretroviral regimens.
    Manavi K; Scott G
    Int J STD AIDS; 2006 Aug; 17(8):522-4. PubMed ID: 16925897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites.
    Jordan MR; Bennett DE; Bertagnolio S; Gilks CF; Sutherland D
    Antivir Ther; 2008; 13 Suppl 2():15-23. PubMed ID: 18575188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.